

NDA 20-547/S-007

Zeneca Pharmaceuticals  
1800 Concord Pike  
P.O.Box 15437  
Wilmington, Delaware 19850-5437

Attention: Mark A. DeSiato  
Senior Regulatory Specialist  
Marketed Products  
Drug Regulatory Affairs Department

Dear Mr. DeSiato:

Please refer to your supplemental new drug application dated September 17, 1998, received September 18, 1998, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Accolate (zafirlukast) 10 mg and 20 mg Tablets.

We acknowledge receipt of your submissions dated October 30, November 4, 19, and 20, 1998, and January 5, and 12, February 11, and 15, March 18, July 9, August 20, 26, and 27, and September 3, 10, 16, and 17, 1999.

This supplemental new drug application provides for the use of Accolate 10 mg for the prophylaxis and chronic treatment of asthma in pediatric patients 7 - 11 years of age.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted September 17, 1999, immediate container and carton labels submitted September 10, 1999).

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-547/S-007." Approval of this submission by FDA is not required before the labeling is used.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 *FR* 66632). We note that you have not fulfilled the requirements of 21 CFR 314.55 (or 601.27). We are deferring submission of your pediatric studies until May 31, 2001.

Pediatric studies conducted under the terms of section 505A of the Federal Food, Drug, and Cosmetics Act may result in additional marketing exclusivity for certain products (pediatric exclusivity). You should refer to the *Guidance for Industry for Qualifying for Pediatric Exclusivity* (available on our web site at [www.fda.gov/cder/pediatric](http://www.fda.gov/cder/pediatric)) for details. The Division will continue to work with you on your request to amend the written request which was issued on January 4, 1999. Please note that satisfaction of the requirements in 21 CFR 314.55 alone may not qualify you for pediatric exclusivity. FDA does not necessarily ask a sponsor to complete the same scope of studies to qualify for pediatric exclusivity as it does to fulfill the requirements of the pediatric rule.

Please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

NDA 20-547/S-007  
Page 3

If you have any questions, contact Ms. Parinda Jani, Project Manager, at (301) 827-1064.

Sincerely yours,

Robert J. Meyer, M.D.  
Director  
Division of Pulmonary and Allergy Drug Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research